Topic
Biosimilars
856 published works
Big Molecule Watch
FDA Approves Lannett, Lanexa Biologics, and Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar
On May 4, 2026, the FDA approved Lannett Company, Inc. (“Lannett”), Lanexa Biologics LLC (“Lanexa”), and Sunshine Lake Pharma’s LANGLARA (insulin glargine-aldy) as an interchangeable biosimilar to Sanofi’s LANTUS (insulin…
Big Molecule Watch
FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars
The U.S. Food and Drug Administration (“FDA”) recently released its congressional justification for the 2027 Fiscal Year budget. Overall, the FDA proposed a total budget of $7.2 billion, an overall…
Big Molecule Watch
Biocon Launches Denosumab Biosimilars
On April 7, 2026, Biocon Limited announced that it had launched BOSAYA (denosumab-kyqq) and AUKELSO (denosumab-kyqq) in the United States. Both products are RANK ligand inhibitors used to treat conditions…
Big Molecule Watch
Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar
On March 30, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) announced that the U.S. Food and Drug Administration (“FDA”) has approved its denosumab biosimilar, PONLIMSI (denosumab-adet). PONLIMSI has been approved for…
Big Molecule Watch
Amgen and Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation
By Riley Wyberg
On March 31, 2026, the District Court for the District of New Jersey entered a Consent Order and Judgment in the BPCIA litigation Amgen brought against Henlius and Organon concerning…
Big Molecule Watch
Bio-Thera and Intas Expand Golimumab Biosimilar Partnership to India
By Yoko Bian
On March 23, 2026, Bio-Thera Solutions announced an expansion of its existing partnership with Intas Pharmaceuticals for BAT2506, its golimumab biosimilar referencing Janssen’s SIMPONI®. The updated agreement grants Intas exclusive…
Big Molecule Watch
Celltrion Announces AVTOZMA (tocilizumab-anoh) Now Available in U.S.
On March 16, 2026, Celltrion, Inc. announced the U.S. commercial launch of AVTOZMA® (tocilizumab-anoh) SC, a subcutaneous formulation of its tocilizumab biosimilar referencing Roche’s ACTEMRA. Celltrion had previously launched its…
Big Molecule Watch
Samsung Bioepis and Sandoz Expand Potential Portfolios Through New Research and Development Collaborations
On March 18, 2026, Sandoz announced a new license, development, and commercialization partnership agreement with Samsung Bioepis Co., Ltd. Under this agreement, the companies will collaborate on the development and…
Big Molecule Watch
Update: Janssen Files BPCIA Complaint Against Bio-Thera and Accord Related to Golimumab Biosimilar
By Natasha Daughtrey|Christopher Cassella
As we reported last week, Janssen Biotech, Inc. and Janssen Sciences Ireland UC (collectively, “Janssen”) filed under seal a BPCIA complaint in the U.S. District Court for the District of…
Big Molecule Watch
FDA Issues Draft Guidance Further Streamlining Biosimilar Development
By Sarah Adam
On March 9, 2026, the U.S. Food and Drug Administration (FDA) issued new draft guidance aimed at further streamlining the development of biosimilar and interchangeable biosimilar products by reducing certain…